To Whom It May Concern,

This is to advise you that FTC staff has reviewed your website at https://revivme.com/ on April 9, 2020. We have determined that you are unlawfully advertising that certain products treat or prevent Coronavirus Disease 2019 (COVID-19).

Some examples of Coronavirus prevention or treatment claims on your website include:

- In marketing materials titled “Coronavirus & the Real Pandemic,” you represent that consumers can “[h]elp protect and prevent against the new strand of virus (known as the Coronavirus) with a REVIV Megaboost IV Therapy containing a high dose of Vitamin C”; and

- In marketing materials titled “High Dose IV Vitamin C Therapy for Viruses and Preventative Health,” you represent that “Vitamin C therapy is once again in the spotlight with its reported effectiveness in the coronavirus pandemic of 2020.... A recent clinical trial conducted in China on coronavirus patients demonstrated that high dose IV Vitamin C therapy decreased duration of hospital stay by about 3-5 days... Furthermore, all subjects receiving IV Vitamin C therapy survived complications from COVID-19.... The same beneficial outcomes could apply to asymptomatic patients or help people suffering mild disease prevent progression. This preventative measure can help keep people out of hospitals...”

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies,
substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any Coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims.

You are also advised to review all other claims for your products and immediately cease making claims that are not supported by competent and reliable scientific evidence.

Within 48 hours, please send a message to James E. Elliott via electronic mail at jelliott@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Zachary A. Keller at zkeller@ftc.gov.

Very truly yours,

[Signature]
Dana J. Brown
Regional Director
Southwest Region